“Small stocks are where the opportunity is greatest, because large institutional investors can't buy them without moving the price. The edge belongs to those who can act small.”
Why this matters.
The title of Tillinghast's book is an investment thesis in four words: institutional size is a liability, not an asset. Large funds with billions under management cannot meaningfully allocate capital to small-capitalization companies without moving the market against themselves. A $10 billion fund taking a 2% position in a $200 million company would need to own the entire company. The practical floor for institutional investment is usually somewhere in the $500 million to $1 billion market-cap range, leaving an enormous universe of smaller companies underanalyzed, underfollowed, and potentially mispriced.
This is the structural edge Tillinghast exploited throughout his career at Fidelity's Low-Priced Stock Fund. He built a process for identifying small, unglamorous companies — often priced below $35 per share when the fund was started, creating a price filter that concentrated the portfolio in smaller businesses — that traded at significant discounts to their intrinsic value precisely because no one was paying attention to them.
For individual investors, this is one of the clearest genuine advantages they hold over institutional competitors. An investor with $100,000 to deploy can buy a meaningful stake in a $50 million company with zero market impact. The research challenge is real — small companies have less coverage, less transparent reporting, and less liquidity — but the analytical playing field is genuinely flatter.
Tillinghast's career is evidence that the small-cap advantage is real and durable. The inefficiency persists because the structural constraint on large institutions is not going away.
